Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Systemic Lupus Erythematosus
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Systemic Lupus Erythematosus or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Systemic Lupus Erythematosus and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
SystemicLupusErythematosus. Systemiclupuserythematosus (lupus) is characterized by aberrant activity of the immune system, leading to variable clinical symptoms. Lupus is more prevalent in African American women and women in other ethnic minority groups. Diagnosing, treating, and identifying novel therapies for lupus is challenging because of its genetic and phenotypic heterogeneity. Lupus nephritis is the most common target-organ manifestation and requires individualized care to minimize (...) toxicity. A multidisciplinary approach to caring for pregnant patients with lupus is essential to optimize outcomes.
Trial of Anifrolumab in Active SystemicLupusErythematosus. Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated for the treatment of systemiclupuserythematosus (SLE), did not have a significant effect on the primary end point in a previous phase 3 trial. The current phase 3 trial used a secondary end point from that trial as the primary end point.We randomly assigned patients in a 1:1 ratio to receive intravenous anifrolumab (300 mg) or placebo every (...) 4 weeks for 48 weeks. The primary end point of this trial was a response at week 52 defined with the use of the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA). A BICLA response requires reduction in any moderate-to-severe baseline disease activity and no worsening in any of nine organ systems in the BILAG index, no worsening on the SystemicLupusErythematosus Disease Activity Index, no increase of 0.3 points or more in the score on the Physician Global
Efficacy and safety of low-dose IL-2 in the treatment of systemiclupuserythematosus: a randomised, double-blind, placebo-controlled trial Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemiclupuserythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy.A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60 patients (...) response rates were 55.17% and 30.00% for IL-2 and placebo, respectively (p=0.052). At week 24, the SRI-4 response rate of IL-2 group was 65.52%, compared with 36.67% of the placebo group (p=0.027). The primary endpoint was not met at week 12. Low-dose IL-2 treatment resulted in 53.85% (7/13) complete remission in patients with lupus nephritis, compared with 16.67% (2/12) in the placebo group (p=0.036). No serious infection was observed in the IL-2 group, but two in placebo group. Besides expansion
Belimumab (Benlysta ) - systemiclupuserythematosus belimumab | CADTH.ca Find the information you need belimumab belimumab Last Updated: October 1, 2019 Result type: Reports Project Number: SR0616-000 Product Line: Generic Name: Belimumab Brand Name: Benlysta Manufacturer: GlaxoSmithKline Inc. Indications: systemiclupuserythematosus Manufacturer Requested Reimbursement Criteria 1 : For the treatment of SLE patients who meet the following eligibility criteria: Adult patients age 18 years
Trends in Maternal and Fetal Outcomes Among Pregnant Women With SystemicLupusErythematosus in the United States: A Cross-sectional Analysis. Although pregnancy in systemiclupuserythematosus (SLE) carries a high risk for mother and fetus, outcomes may be improving.To assess nationwide trends and disparities in maternal and fetal complications among pregnant women with SLE.Retrospective cohort study.United States, 1998 to 2015.Adult pregnant women with and without SLE who had hospitalizations
Novel paradigms in systemiclupuserythematosus. The heterogeneity of systemiclupuserythematosus (SLE), long recognised by clinicians, is now challenging the entire lupus community, from geneticists to clinical investigators. Although the outlook for patients with SLE has greatly improved, many unmet needs remain, chief of which is the development of safer and more efficacious therapies. To develop innovative therapies, a far better understanding of SLE pathogenesis as it relates to the array (...) of clinical phenotypes is needed. Additionally, to efficiently achieve these goals, the lupus community needs to refine existing clinical research tools and better adapt them to overcome the obstacles created by the heterogeneity of manifestations. Here, we review progress towards the ultimate goal of safely reducing disease activity and preventing damage accrual and death. We discuss the new classification criteria from the European League Against Rheumatism and American College of Rheumatology, novel
Management strategies and future directions for systemiclupuserythematosus in adults. Systemiclupuserythematosus (SLE) is an autoimmune disease characterised by the loss of self-tolerance and formation of nuclear autoantigens and immune complexes resulting in inflammation of multiple organs. The clinical presentation of SLE is heterogeneous, can involve one or more organs, including the skin, kidneys, joints, and nervous system, and take a chronic or relapsing and remitting disease course
Comparison of Sensitivities of American College of Rheumatology and SystemicLupus International Collaborating Clinics Classification Criteria in Childhood-onset SystemicLupusErythematosus Currently there are 2 different classification criteria for systemiclupuserythematosus (SLE): American College of Rheumatology (ACR) and SystemicLupus International Collaborating Clinics (SLICC). The aim of this study was to compare the sensitivities of ACR and SLICC criteria in childhood-onset SLE (cSLE (...) ) using a large, multiethnic cohort.We conducted a retrospective study of 722 patients diagnosed with cSLE at The Hospital for Sick Children (SickKids). Prospectively collected data from SickKids' Lupus Database were reviewed/validated against medical records prior to ACR and SLICC scoring based on cumulative symptoms up to the last visit. Sensitivities were compared using McNemar's test. Descriptive statistics were used to identify SLE features unique to each set of criteria and autoantibodies
Bidirectional relationship between systemiclupuserythematosus and non-Hodgkin`s lymphoma: a nationwide population-based study We conducted this nationwide population-based study in Taiwan to investigate whether there is a bidirectional relationship between SLE and non-Hodgkin's lymphoma (NHL).Using the National Health Insurance Research Database of Taiwan, we identified 16 417 patients with new-onset SLE without previous cancer and 25 069 patients with new-onset NHL without previous SLE
Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with SystemicLupusErythematosus Composite scores of cardiovascular (CV) risk factors underestimate the CV risk in patients with systemiclupuserythematosus (SLE). Carotid artery ultrasound (US) was found useful in identifying high CV-risk patients with inflammatory arthritis. We assessed the effect of carotid US assessments on the CV risk stratification of patients with SLE.This cross (...) -sectional study included 276 patients with SLE. These indices were measured: lipid profile, Systematic COronary Risk Evaluation (SCORE) risk calculation, and disease activity (SLE Disease Activity Index), severity (Katz), and damage [SystemicLupus International Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index]. Carotid plaques were assessed by US. A multivariable regression analysis, adjusted for classic CV-related factors, was performed to evaluate how risk reclassification
Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of SystemicLupusErythematosus To develop recommendations for the assessment of people with systemiclupuserythematosus (SLE) in Canada.Recommendations were developed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. The Canadian SLE Working Group (panel of Canadian rheumatologists and a patient representative from Canadian Arthritis Patient Alliance) was created
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemiclupuserythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. IL-12 and IL-23 have been implicated in systemiclupuserythematosus. We aimed to assess the efficacy and safety (...) of ustekinumab for the treatment of systemiclupuserythematosus in patients with moderate-to-severe disease activity despite conventional treatment.This was a multicentre, double-blind, phase 2, randomised, controlled trial of adult patients with active, seropositive systemiclupuserythematosus, done at 44 private practices and academic centres in Argentina, Australia, Germany, Hungary, Mexico, Poland, Spain, Taiwan, and the USA. Eligible adults were aged 18-75 years, weighed at least 35 kg, and had
2018LancetControlled trial quality: predicted high
Evidence of a distinct group of Black African patients with systemiclupuserythematosus The autoimmune disease systemiclupuserythematosus (SLE) occurs more frequently in patients of African descent with high morbidity and mortality. Current SLE diagnostic criteria including antinuclear antibody (ANA) reactivity are derived largely from non-African populations. This study characterises ANA reactivity patterns and relates them to SLE clinical presentation in Black African patients.Sera from
Catalytic antibodies in patients with systemiclupuserythematosus Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemiclupuserythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglobulin G (IgG) of SLE patients from
Baricitinib for systemiclupuserythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Patients with systemiclupuserythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemiclupus erythematosus.In this double-blind, multicentre, randomised, placebo-controlled, 24-week phase 2 study, patients were recruited from 78 centres in 11 (...) countries. Eligible patients were aged 18 years or older, had a diagnosis of systemiclupuserythematosus, and had active disease involving skin or joints. We randomly assigned patients (1:1:1) to receive once-daily baricitinib 2 mg, baricitinib 4 mg, or placebo for 24 weeks. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by SystemicLupusErythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all
2018LancetControlled trial quality: predicted high
Systemiclupuserythematosus Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Proof of concept – note only works for conditions, do not add interventions into the search box! This is a beta ‘proof of concept’ of a fully automated evidence mapping system. It is experimental and therefore the results should be dealt with appropriate scepticism. To understand more of what the system does . Please send feedback to (we will only get better by constructive feedback). For a list
Musculoskeletal involvement and ultrasonography update in systemiclupuserythematosus: New insights and review Ultrasonography has been rarely used to measure musculoskeletal and joint activity in systemiclupuserythematosus (SLE). The aim of this review is to discuss the utility and reliability of this non-invasive diagnostic tool for the assessment of joint disease in SLE patients. In the last decade, several reports have highlighted the role of ultrasonography for a better evaluation